share_log

Elevance Health's (NYSE:ELV) Solid Earnings Have Been Accounted For Conservatively

Elevance Health's (NYSE:ELV) Solid Earnings Have Been Accounted For Conservatively

保守地考虑了Elevance Health(纽约证券交易所代码:ELV)的稳健收益
Simply Wall St ·  04/25 07:51

Investors signalled that they were pleased with Elevance Health, Inc.'s (NYSE:ELV) most recent earnings report. According to our analysis of the report, the strong headline profit numbers are supported by strong earnings fundamentals.

投资者表示,他们对Elevance Health, Inc.感到满意。”s(纽约证券交易所代码:ELV)最新的收益报告。根据我们对报告的分析,强劲的总体利润数字得到了强劲的收益基本面的支持。

earnings-and-revenue-history
NYSE:ELV Earnings and Revenue History April 25th 2024
纽约证券交易所:ELV 收益和收入历史记录 2024 年 4 月 25 日

The Impact Of Unusual Items On Profit

不寻常物品对利润的影响

Importantly, our data indicates that Elevance Health's profit was reduced by US$1.1b, due to unusual items, over the last year. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And that's hardly a surprise given these line items are considered unusual. Assuming those unusual expenses don't come up again, we'd therefore expect Elevance Health to produce a higher profit next year, all else being equal.

重要的是,我们的数据表明,由于异常项目,Elevance Health的利润比去年减少了11亿美元。看到不寻常的项目使公司利润付出代价从来都不是一件好事,但从好的方面来看,情况可能迟早会好转。我们调查了数千家上市公司,发现不寻常的物品本质上往往是一次性的。鉴于这些单列项目被认为不寻常,这并不奇怪。假设这些不寻常的支出不会再次出现,因此,在其他条件相同的情况下,我们预计Elevance Health明年将产生更高的利润。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

这可能会让你想知道分析师对未来盈利能力的预测。幸运的是,您可以单击此处查看根据他们的估计描绘未来盈利能力的交互式图表。

Our Take On Elevance Health's Profit Performance

我们对Elevance Health利润表现的看法

Because unusual items detracted from Elevance Health's earnings over the last year, you could argue that we can expect an improved result in the current quarter. Because of this, we think Elevance Health's earnings potential is at least as good as it seems, and maybe even better! And the EPS is up 40% annually, over the last three years. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. Case in point: We've spotted 1 warning sign for Elevance Health you should be aware of.

由于不寻常的项目削弱了Elevance Health去年的收益,你可能会争辩说,我们可以预期本季度的业绩会有所改善。因此,我们认为Elevance Health的盈利潜力至少和看起来一样好,甚至可能更好!在过去三年中,每股收益每年增长40%。本文的目标是评估我们在多大程度上可以依靠法定收益来反映公司的潜力,但还有很多需要考虑的地方。请记住,在分析股票时,值得注意所涉及的风险。一个很好的例子:我们发现了一个你应该注意的 Elevance Health 警告信号。

Today we've zoomed in on a single data point to better understand the nature of Elevance Health's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

今天,我们放大了单一数据点,以更好地了解Elevance Health利润的性质。但是,如果你能够将注意力集中在细节上,总会有更多的事情需要发现。例如,许多人认为高股本回报率是有利的商业经济的标志,而另一些人则喜欢 “关注资金”,寻找内部人士正在买入的股票。因此,你可能希望看到这份免费收藏的拥有高股本回报率的公司,或者这份内部人士正在购买的股票清单。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发